<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02755857</url>
  </required_header>
  <id_info>
    <org_study_id>MPG011</org_study_id>
    <nct_id>NCT02755857</nct_id>
  </id_info>
  <brief_title>Bioavailability Study of Lozanoc™ 65 mg Itraconazole Capsules in Patients Requiring Prophylaxis</brief_title>
  <official_title>A Single-arm, Multiple-Dose, Steady-State, Bioavailability Study With Twice Daily Dosing of Lozanoc™ (65 mg Itraconazole Capsules, Mayne) Taken Regardless of Food</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayne Pharma International Pty Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayne Pharma International Pty Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This open-labelled, single arm study is a follow-on from Study MPG010 to compare the relative&#xD;
      bioavailability of Lozanoc 65 mg Capsules against Lozanoc 50 mg Capsules and Sporanox 100 mg&#xD;
      Capsules in patients requiring itraconazole anti-fungal prophylaxis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After confirmation of eligibility, participants will take their last dose of current&#xD;
      itraconazole therapy (Lozanoc 50mg capsules or Sporanox 100mg capsules) on the morning of Day&#xD;
      1, and commence therapy with Lozanoc 65 mg capsules for 21 days from the evening of Day 1.&#xD;
&#xD;
      The number of Lozanoc 65mg capsules to be taken by the participant will be 2 capsules (130mg)&#xD;
      morning and evening OR the same number of Lozanoc 50mg capsules that the participant received&#xD;
      in study MPG010, if applicable. That is, if the participant received 3 x 50mg Lozanoc&#xD;
      capsules morning and evening on study MPG010 he/she will receive 3 x 65 mg Lozanoc 65 mg&#xD;
      capsules, morning and evening in study MPG011&#xD;
&#xD;
      The dose of study drug (Lozanoc 65mg) may be dose-reduced or ceased for toxicity at the&#xD;
      discretion of the investigator.&#xD;
&#xD;
      Participants will undergo the following assessments during the course of the study:&#xD;
&#xD;
        -  Concurrent medication(s)&#xD;
&#xD;
        -  Clinical adverse events&#xD;
&#xD;
        -  Measurement of vital signs (weight, blood pressure, temperature)&#xD;
&#xD;
        -  Targeted physical examination&#xD;
&#xD;
        -  Documentation of any evidence of systemic fungal infection&#xD;
&#xD;
        -  Medication and meal diaries&#xD;
&#xD;
        -  12-lead electrocardiogram (ECG)&#xD;
&#xD;
        -  Laboratory safety assessments&#xD;
&#xD;
             -  Renal function and electrolytes (urea, creatinine, estimated glomerular filtration&#xD;
                rate [eGFR], sodium, potassium, chlorine, bicarbonate)&#xD;
&#xD;
             -  Liver function tests (bilirubin, albumin, total protein, alanine aminotransferase&#xD;
                [ALT], aspartate aminotransferase [AST])&#xD;
&#xD;
        -  Pharmacokinetic testing&#xD;
&#xD;
             -  pre-morning dose (0 h sample) at Baseline (Day 1), and at Days 8, 15, and 22&#xD;
&#xD;
             -  at 2, 3.5 and 6 hours post the morning dose at Baseline (Day 1) and Day 22&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 2016</start_date>
  <completion_date type="Actual">January 2017</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Steady-state plasma itraconazole concentrations</measure>
    <time_frame>3 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Neutropenia</condition>
  <arm_group>
    <arm_group_label>Lozanoc</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>65 mg, capsules, at least 2 capsules twice a day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lozanoc</intervention_name>
    <description>65 mg</description>
    <arm_group_label>Lozanoc</arm_group_label>
    <other_name>itraconazole</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Provision of written, informed consent&#xD;
&#xD;
          -  Age of at least 18 years&#xD;
&#xD;
          -  No clinical evidence of active systemic fungal infection&#xD;
&#xD;
          -  Physician-recommended continuation of oral itraconazole as primary prophylaxis in&#xD;
             patients at risk of systemic fungal infections or otherwise requiring a long-term&#xD;
             itraconazole maintenance regimen, including patients:&#xD;
&#xD;
               -  who have had or are about to have a heart, lung or bone marrow transplant&#xD;
&#xD;
               -  on combination chemotherapy for cancer&#xD;
&#xD;
               -  with an aspergilloma, chronic pulmonary aspergillus bronchitis, or allergic&#xD;
                  bronchopulmonary aspergillosis&#xD;
&#xD;
          -  At least 21 days of prior dosing with oral itraconazole, either Lozanoc 50mg capsules&#xD;
             twice daily or Sporanox 100mg capsules twice daily.&#xD;
&#xD;
          -  Body mass index between 15.0 and 35.0 kg/m2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant, planning pregnancy or breastfeeding&#xD;
&#xD;
          -  Plasma itraconazole concentration greater than 1500ng/mL (in patients on Lozanoc 50mg&#xD;
             capsules)&#xD;
&#xD;
          -  Congestive cardiac failure or other causes of ventricular dysfunction that may&#xD;
             outweigh the benefit of itraconazole&#xD;
&#xD;
          -  Hypersensitivity to Lozanoc or to any of its excipients&#xD;
&#xD;
          -  Coadministration of the following drugs:&#xD;
&#xD;
               -  CYP3A4 metabolised substrates that can prolong the QT-interval: sertindole,&#xD;
                  terfenadine&#xD;
&#xD;
               -  CYP3A4 metabolised 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase&#xD;
                  inhibitors: simvastatin, lovastatin&#xD;
&#xD;
               -  Potent CYP3A4 inhibitor: dronedarone&#xD;
&#xD;
               -  Triazolam, alprazolam and oral midazolam&#xD;
&#xD;
               -  Ergot alkaloids such as dihydroergotamine, ergometrine (ergonovine) and&#xD;
                  ergotamine&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Deborah Marriott, MBBS BSc(MED) FRACP FRCPA</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Vincent's Hospital-Manhattan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St Vincent's Hospital</name>
      <address>
        <city>Darlinghurst</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>April 28, 2016</study_first_submitted>
  <study_first_submitted_qc>April 28, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 29, 2016</study_first_posted>
  <last_update_submitted>October 24, 2018</last_update_submitted>
  <last_update_submitted_qc>October 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prophylaxis</keyword>
  <keyword>Bioavailability</keyword>
  <keyword>Pharmacokinetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neutropenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Itraconazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Individual patient data will not be made available</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

